Precision BioSciences, Inc. (DTIL)

0.3850 +0.0020 (+0.52%) As of 02:15PM EST. Market open.

Precision BioSciences, Inc.

302 East Pettigrew Street
Suite A-100
Durham, NC 27701
United States
919 314 5512
https://www.precisionbiosciences.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 115

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Michael Amoroso	President, CEO & Director	979.04k	N/A	1978
Mr. John Alexander Kelly R.Ph.	CFO & Principal Accounting Officer	623.58k	N/A	1967
Mr. Dario Scimeca	General Counsel & Secretary	576.43k	N/A	1976
Dr. Derek Jantz Ph.D.	Co-Founder & Chief Science Advisor	597.38k	N/A	1976
Dr. Jefferson J. Smith Ph.D.	Co-Founder & Chief Research Officer	N/A	N/A	1973
Mei Burris	Director of Investor Relations & Finance	N/A	N/A	N/A
Mr. Bruce Stevens	Vice President of Quality & Compliance	N/A	N/A	N/A
Maurissa Messier	Senior Director of Corporate Communications	N/A	N/A	N/A
Ms. Juli Blanche	Chief People Officer	N/A	N/A	N/A
Mr. Garrett Gincley	Head of Manufacturing	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Corporate governance

Precision BioSciences, Inc.’s ISS governance QualityScore as of 28 November 2023 is 7. The pillar scores are Audit: 3; Board: 6; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.